Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

Johann K. Hitzler, Todd A. Alonzo, Robert Gerbing, Jim Wang, Amy Beckman, Betsy Hirsch, Susana C. Raimondi, Karen M Chisholm, Shelton A. Viola, Anupam Verma, Lisa Eidenschink Brodersen, Michael R. Loken, Jeffrey W. Taub, Alan S Gamis, E. Anders Kolb, Todd M Cooper, Jason N. Berman

Blood (2024) 144 (Supplement 1): 2949.

https://doi.org/10.1182/blood-2024-202621

Published: 2024

Journal Articles

A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO - a Report from the Children's Oncology Group

Blood (2024) 144 (Supplement 1): 967.

https://doi.org/10.1182/blood-2024-205666

Published: 2024

Journal Articles

Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial

Michele S. Redell, Robert Gerbing, Todd A. Alonzo, Jim Wang, Maureen O'Brien, Sarah K. Tasian, Matthew A. Kutny, Todd M Cooper

Blood (2024) 144 (Supplement 1): 4233.

https://doi.org/10.1182/blood-2024-200978

Published: 2024

Journal Articles

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Michele S. Redell, Todd A. Alonzo, Robert Gerbing, Jim Wang, Maureen M. O'Brien, Gwen Nichols, Laura Di Laurenzio, Sarah K. Tasian, C. Michel Zwaan, Dirk Reinhardt, E. Anders Kolb, Todd Cooper

Blood (2023) 142 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2023-190947

Published: 2023

Journal Articles

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Blood (2021) 138 (23): 2337–2346.

https://doi.org/10.1182/blood.2021012206

Published: 2021

Includes: Supplemental data

Journal Articles

Excess Treatment-Related Mortality in Obese Children and Adolescents with Acute Myeloid Leukemia on AAML0531: A Report from the Children's Oncology Group

Lillian Sung, MD PhD FRCPC, Robert Gerbing, BS, Todd A. Alonzo, PhD, Yi-Cheng Wang, MS, Etan Orgel, MD MS, Alan S. Gamis, MD MPH, Richard Aplenc, MD PhD

Blood (2016) 128 (22): 2790.

https://doi.org/10.1182/blood.V128.22.2790.2790

Published: 2016

Journal Articles

Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) As a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative

Blood (2016) 128 (22): 2873.

https://doi.org/10.1182/blood.V128.22.2873.2873

Published: 2016

Journal Articles

Mutational Concordance from Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Katherine Tarlock, MD, Todd M Cooper, DO, Todd A. Alonzo, PhD, Robert Gerbing, BS, Jessica Pollard, MD, Richard Aplenc, MD PhD, E. Anders Kolb, MD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD

Blood (2016) 128 (22): 2846.

https://doi.org/10.1182/blood.V128.22.2846.2846

Published: 2016

Journal Articles

Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration

Dalia Selim, MD, Todd A. Alonzo, PhD, Megan Othus, PhD, Robert Gerbing, BS, Fabiana Ostronoff, MD, Katherine Tarlock, MD, Matthew A. Kutny, MD, Richard Aplenc, MD PhD, E. Anders Kolb, MD, Jerald P. Radich, MD, Frederick R. Appelbaum, MD, Alan S. Gamis, MD MPH, Derek L. Stirewalt, Soheil Meshinchi, MD PhD

Blood (2016) 128 (22): 285.

https://doi.org/10.1182/blood.V128.22.285.285

Published: 2016

Journal Articles

FLT3 Mutations in Pediatric Acute Promyelocytic Leukemia; A Report from the Children's Oncology Group AAML0631 Trial

Matthew A. Kutny, MD, Todd A. Alonzo, PhD, Robert Gerbing, BS, Yi-Cheng Wang, Cecilia Fu, MD, Alan S. Gamis, MD MPH, E. Anders Kolb, MD, James H. Feusner, MD, John Gregory, Jr., MD, Soheil Meshinchi, MD PhD

Blood (2016) 128 (22): 2884.

https://doi.org/10.1182/blood.V128.22.2884.2884

Published: 2016

Journal Articles

Prognostic Significance of 11q23/ MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531

Erin M. Guest, MD, Betsy A. Hirsch, PhD, E. Anders Kolb, MD, Todd A. Alonzo, PhD, Robert Gerbing, BS, Richard Aplenc, MD PhD, Jessica Pollard, MD, Lillian Sung, MD PhD FRCPC, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH, Susana C. Raimondi, PhD

Blood (2016) 128 (22): 1211.

https://doi.org/10.1182/blood.V128.22.1211.1211

Published: 2016

Journal Articles

The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group

Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD, Lillian Sung, MD PhD FRCPC, Todd A. Alonzo, PhD, Jessica Pollard, MD, Robert Gerbing, BS, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Michael R. Loken, PhD, Laura Winter, PharmD, Samir B. Kahwash, John K Choi, MD, John E Levine, MD MS, E. Anders Kolb, MD, Alan S. Gamis, MD MPH

Blood (2016) 128 (22): 899.

https://doi.org/10.1182/blood.V128.22.899.899

Published: 2016

Journal Articles

Functional Polymorphisms in Oxidant Metabolism and DNA Repair Pathways and Risk of Leukemia and Transient Myeloproliferative Disorder in Children with Down Syndrome

Melissa S Rayburg, MD, Mi-Ok Kim, Todd Alonzo, PhD, Robert Gerbing, Gretchen A Radloff, Stella M Davies, Alan Gamis, MD, John Perentesis

Blood (2008) 112 (11): 2947.

https://doi.org/10.1182/blood.V112.11.2947.2947

Published: 2008

Journal Articles

High Level Expression of Wild Type FLT3 Is Associated with Poor Outcome and Selective Sensitivity to FLT3 Inhibitors in Childhood Acute Myeloid Leukemia: A Children’s Oncology Group Study

Patrick Brown, MD, Todd Alonzo, PhD, Robert Gerbing, Emily McIntyre, Beverly Lange, MD, Donald Small, Soheil Meshinchi, MD, PhD

Blood (2008) 112 (11): 147.

https://doi.org/10.1182/blood.V112.11.147.147

Published: 2008

Journal Articles

Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group

Jessica A Pollard, Rong Zeng, Phoenix Ho, Todd Alonzo, PhD, Robert Gerbing, Derek Stirewalt, Nyla A. Heerema, PhD, Susana C. Raimondi, PhD, Betsy Hirsch, Janet Franklin, MD, MPH, Beverly Lange, MD, Soheil Meshinchi, MD, PhD

Blood (2008) 112 (11): 143.

https://doi.org/10.1182/blood.V112.11.143.143

Published: 2008

Journal Articles

Correlation of CD 33 Expression Level with Disease Characteristics and Response to Gemtuzumab Ozogamycin-Containing Chemotherapy in Childhood AML

Jessica A Pollard, Todd Alonzo, PhD, Robert Gerbing, Susana C. Raimondi, PhD, Betsy Hirsch, Janet Franklin, MD, MPH, Alan Gamis, MD, Michael R Loken, Soheil Meshinchi, MD, PhD

Blood (2008) 112 (11): 148.

https://doi.org/10.1182/blood.V112.11.148.148

Published: 2008

Journal Articles

COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML)

Janet Franklin, MD, MPH, Todd Alonzo, PhD, Craig Alan Hurwitz, MD, Robert Gerbing, Franklin Smith, Robert J. Arceci, MD, PhD, James Feusner, MD, Prasad Mathew, MD, Robert Iannone, MD, Soheil Meshinchi, MD, PhD, Robert Lavey, MD, MPH, Joetta D Wallace, RN, Kelly Anderson, RN, Laura Winter, PharmD, Kathleen Glick, BA, Betty Hirsch, MD, Susana C. Raimondi, PhD, Alan Gamis, MD

Blood (2008) 112 (11): 136.

https://doi.org/10.1182/blood.V112.11.136.136

Published: 2008

Journal Articles

Clinical and Serologic Interleukin 2 Receptor α Response to Interleukin-2 in CCG-2961, a Ranomized Phase 3 Trial for Pediatric Acute Myeloid Leukemia.

Beverly Lange, MD, Richard K Yang, Jacek Gan, PhD, Jaqueline A Hank, PhD, Eric Sievers, MD, Robert Gerbing, Todd Alonzo, PhD, Paul M Sondel, MD, PhD

Blood (2008) 112 (11): 959.

https://doi.org/10.1182/blood.V112.11.959.959

Published: 2008

Journal Articles

Pediatric Patients with Extramedullary Leukemia Involving the Central Nervous System Have a Superior Outcome.

Donna Johnston, MD, FRCPC, Todd Alonzo, PhD, Robert Gerbing, Beverly Lange, MD, William G. Woods, MD

Blood (2008) 112 (11): 920.

https://doi.org/10.1182/blood.V112.11.920.920

Published: 2008

Journal Articles

Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols.

Jessica Pollard, Todd Alonzo, Robert Gerbing, Rong Zeng, Betsy Hirsch, Susana Raimondi, Nyla Heerema, William Woods, Beverly Lange, Craig Hurwitz, Robert Arceci, Jerald Radich, Irwin Bernstein, Michael Heinrich, Soheil Meshinchi

Blood (2007) 110 (11): 1442.

https://doi.org/10.1182/blood.V110.11.1442.1442

Published: 2007

NARROW

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO - a Report from the Children's Oncology Group

Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Excess Treatment-Related Mortality in Obese Children and Adolescents with Acute Myeloid Leukemia on AAML0531: A Report from the Children's Oncology Group

Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) As a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative

Mutational Concordance from Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration

FLT3 Mutations in Pediatric Acute Promyelocytic Leukemia; A Report from the Children's Oncology Group AAML0631 Trial

Prognostic Significance of 11q23/ MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531

The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group

Functional Polymorphisms in Oxidant Metabolism and DNA Repair Pathways and Risk of Leukemia and Transient Myeloproliferative Disorder in Children with Down Syndrome

High Level Expression of Wild Type FLT3 Is Associated with Poor Outcome and Selective Sensitivity to FLT3 Inhibitors in Childhood Acute Myeloid Leukemia: A Children’s Oncology Group Study

Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group

Correlation of CD 33 Expression Level with Disease Characteristics and Response to Gemtuzumab Ozogamycin-Containing Chemotherapy in Childhood AML

COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML)

Clinical and Serologic Interleukin 2 Receptor α Response to Interleukin-2 in CCG-2961, a Ranomized Phase 3 Trial for Pediatric Acute Myeloid Leukemia.

Pediatric Patients with Extramedullary Leukemia Involving the Central Nervous System Have a Superior Outcome.

Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only